Association of urinary N-domain angiotensin I-converting enzyme with plasma inflammatory markers and endothelial function

Molecular Medicine

Volumn 14, Issue 7-8, 2008, Pages 429-435

  Fernandes, Fernanda B ^a   Plavnik, Frida L ^a   Teixeira, Andressa M S ^a   Christofalo, Dejaldo M J ^a   Ajzen, Sergio A ^a   Higa, Elisa M S ^a   Ronchi, Fernanda A ^a   Sesso, Ricardo C C ^a   Casarini, Dulce E ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; HOMOCYSTEINE; NITRIC OXIDE;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CHEMISTRY; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOPPLER FLOWMETRY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FAMILY HISTORY; HUMAN; HYPEREMIA; HYPERTENSION; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FAMILY HEALTH; HOMOCYSTEINE; HUMANS; HYPERTENSION; INFLAMMATION; MALE; PEPTIDYL-DIPEPTIDASE A; PROTEIN STRUCTURE, TERTIARY; VASODILATION;

EID: 48149108589     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2007-00112.Fernandes     Document Type: Article

References (44)

1. Lloyd-Jones DM, Bloch KD. (1996) The vascular biology of nitric oxide and its role in atherogenesis. Annu. Rev. Med. 47:365-75.
2. Yan CKD, Aizawa T, Berk BC. (2003) Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscler. Thromb. Vasc. Biol. 23:26-36.
3. Mancini GB et al. (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 94:258-65.
4. Yusuf S et al. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:145-53.
5. Skeggs LT Jr, Kahn JR, Shumway NP. (1956) The preparation and function of the hypertensin-converting enzyme. J. Exp. Med. 103:295-9.
6. Yang HY, Erdos EG, Levin Y. (1970) A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim. Biophys. Acta. 214:374-6.
7. Fleming, I. (2006) Signaling by the angiotensin-converting enzyme. Circ. Res. 98:887-96.
8. Soubrier F et al. (1988) Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. U. S. A. 85:9386-90.
9. Erdös EG, Skidgel RA. (1987) The angiotensin I-converting enzyme. Lab. Invest. 56:345-8.
10. Lanzillo JJ, Stevens J, Dasarathy Y, Yotsumoto H, Fanburg BL. (1985) Angiotensin-converting enzyme from human tissues. Physicochemical, catalytic, and immunological properties. J. Biol. Chem. 260:14938-44.
11. Lantz I, Thörnwall M, Kihlström JE, Nyberg F. (1992) A comparison of human lung, brain, CSF and plasma angiotensin-converting enzyme with regard to neuropeptide metabolism. Biochem. Int. 26:415-26.
12. Johnston CI. (1992) Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J. Hypertens. Suppl. 10:S13-26.
13. Casarini DE et al. (1995) Calcium channel blockers as inhibitors of angiotensin I-converting enzyme. Hypertension. 26:1145-8.
14. Casarini DE et al. (1991) Effect of diuretics upon urinary levels of angiotensin converting enzyme (ACE) of essential mild hypertensive patients (EHP). Hypertension. 16:463. Abstract.
15. Casarini DE et al. (2001) Angiotensin converting enzymes from human urine of mild hypertensive untreated patients resemble the N-terminal fragment of human angiotensin I-converting enzyme. Int. J. Biochem. Cell. Biol. 33:75-85.
16. Marques GD et al. (2003) N-domain angiotensin I-converting enzyme with 80 kDa as a possible genetic marker of hypertension. Hypertension. 42:693-701.
17. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. (1990) Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 323:22-7.
18. McAllister AS et al. (1999) Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin. Sci. (Lond). 97:141-7.
19. Libby P, Ridker PM, Maseri A. (2002) Inflammation and atherosclerosis. Circulation. 105:1135-43.
20. Jialal I, Devaraj S. (2003) Role of C-reactive protein in the assessment of cardiovascular risk. Am. J. Cardiol. 91:200-2.
21. Cleland SJ et al. (2000) Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin. Sci. (Lond). 98:531-5.
22. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. (2004) Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am. J. Hypertens. 17:568-73.
23. Ridker PM. (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 107:363-9.
24. Ueland PM, Refsum H, Beresford SA, Vollset SE. (2000) The controversy over homocysteine and cardiovascular risk. Am. J. Clin. Nutr. 72:324-32.
25. Piquilloud Y, Reinharz A, Roth M. (1970) Studies on the angiotensin converting enzyme with different substrates. Biochim. Biophys. Acta. 206:136-42.
26. Friedland J, Silverstein E. (1976) A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am. J. Clin. Pathol. 66:416-24.
27. Bradford MM. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-54.
28. Laemmli UK. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680-5.
29. Bruneval P et al. (1986) Angiotensin I converting enzyme in human intestine and kidney. Ultrastructural immunohistochemical localization. Histochemistry. 85:73-80.
30. Celenmajer DS et al. (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1111-5.
31. Pfeiffer CM, Huff DL, Gunter EW. (1999) Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. Clin. Chem. 45:290-2.
32. Nunes EC et al. (2000) Standardization of homocysteine determination by high pressure liquid chromatography and application on coronary artery disease patients. J. Bras. Patol. 36:166-73.
33. Ribeiro L et al. (2004) Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents. Kidney Int. 65:589-96.
34. Luft FC. (1998) Molecular genetics of human hypertension. J. Hypertens. 16:1871-8.
35. Hooper NM. (1991) Angiotensin converting enzyme: implications from molecular biology for its physiological functions. Int. J. Biochem. 23:641-7.
36. Beldent V, Michaud A, Bonnefoy C, Chauvet MT, Corvol P. (1995) Cell surface localization of proteolysis of human endothelial angiotensin I-converting enzyme. Effect of the amino-terminal domain in the solubilization process. J. Biol. Chem. 270:28962-9.
37. Williams TA, Danilov S, Alhenc-Gelas F, Soubrier F. (1996) A study of chimeras constructed with the two domains of angiotensin I-converting enzyme. Biochem. Pharmacol. 51:11-4.
38. Rogers J et al. (1980) Two mRNAs with different 3' ends encode membrane-bound and secreted forms of immunoglobulin mu chain. Cell. 20:303-12.
39. Sugimura K, Tian XL, Hoffmann S, Ganten D, Bader M. (1998) Alternative splicing of the mRNA coding for the human endothelial angiotensin-converting enzyme: a new mechanism for solubilization. Biochem. Biophys. Res. Commun. 247:466-72.
40. Taddei S, Virdis A, Mattei P, Arzilli F, Salvetti A. (1992) Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J. Cardiovasc. Pharmacol. 20 Suppl 12:S193-5.
41. Treasure CB et al. (1992) Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ. Res. 71:776-81.
42. Lyamina NP, Dolotovskaya PV, Lyamina SV, Malyshev IY, Manukhina EB. (2003) Nitric oxide production and intensity of free radical processes in young men with high normal and hypertensive blood pressure. Med. Sci. Monit. 9:CR304-10.
43. Refsum H, Guttormsen AB, Fiskerstrand T, Ueland PM. (1998) Hyperhomocysteinemia in terms of steady-state kinetics. Eur. J. Pediatr. 157 Suppl 2:S45-9.
44. Clapp BR et al. (2005) Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation. 111:1530-6.